Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Fujifilm Diosynth Renews MHRA License | Contract Pharma

What are you searching for?

Sign in
Breaking News

Fujifilm Diosynth Renews MHRA License

Authorizes commercial manufacturing at Billingham, UK site

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Fujifilm Diosynth Biotechnologies has received a renewal of its Manufacturer’s License from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). The license authorizes commercial manufacturing at the company’s Billingham, UK site.
 
The inspection included the new cGMP mammalian cell culture manufacturing facility, which will primarily employ single-use technologies. It will initially offer 200L and 1000L single-use bioreactors, with 2000L bioreactors planned for 2014. The license also covers commercial manufacturing of microbial-based biologics in the company’s large scale manufacturing assets. The company currently has FDA-approval for the manufacture of two commercial products at these facilities.
 
Steve Bagshaw, managing director of Fujifilm Diosynth Biotechnologies’ UK site, said, “We are delighted to have received a renewal of our Manufacturer’s License from the MHRA. Our customers can be assured that this demonstrates our commitment to quality and ultimately patient care, and confirms our position as a top player in the CMO field for both microbial and mammalian biopharmaceuticals.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics